XBiotech, Inc. Stock

$2.98

0.67% day before yesterday

Nasdaq, Jul 18, 10:00 pm CET

ISIN

CA98400H1029

Symbol

XBIT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

XBiotech, Inc. Stock price

$2.98

-10.53 77.95% 5Y

Nasdaq, Closing price Fri, Jul 18 2025

-0.02 0.67%

ISIN

CA98400H1029

Symbol

XBIT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$90.9m

Enterprise Value

$-65.1m

Net debt

positive

Cash

$155.9m

Shares outstanding

30.5m

Valuation (TTM | estimate)

P/E

negative | -

P/S

- | -

EV/Sales

- | -

EV/FCF

2.1

P/B

0.5

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$0.0 | -

EBITDA

$-43.5m | -

EBIT

$-45.2m | -

Net Income

$-39.4m | -

Free Cash Flow

$-31.6m

Financial Health

Equity Ratio

91.6%

Return on Equity

-21.4%

ROCE

-25.6%

ROIC

-181.7%

Debt/Equity

0.0

EPS

$-1.3

FCF per Share

$-1.0

Short interest

5.0%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

XBiotech, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a XBiotech, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a XBiotech, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from XBiotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	5.62 5.62	18% 18% -
- Research and Development Expense	40 40	9% 9% -
EBITDA	-43 -43	10% 10% -
- Depreciation and Amortization	1.76 1.76	2% 2% -
EBIT (Operating Income) EBIT	-45 -45	9% 9% -
Net Profit	-39 -39	28% 28% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

XBiotech, Inc. Stock News

Neutral

GlobeNewsWire

●

6 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

Company Profile

XBiotech, Inc. is a biopharmaceutical company. The firm engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Head office	Canada
CEO	John Simard
Employees	92
Founded	2005
Website	www.xbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now